A Phase 2 interventional study of TYRA-300 0.125 mg/kg and TYRA-300 0.25 mg/kg in Achondroplasia, sponsored by Tyra Biosciences, Inc. Recruiting at 25 sites in 8 countries. Open to participants aged 3 Years to 10 Years. Per ClinicalTrials.gov, last updated 2026-10-01.
Sponsored by Tyra Biosciences, Inc · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies in Achondroplasia with a site in United States — 8 open to participants now, 11 under way, 3 of them phase 3. Achondroplasia · United States.
Among the 29 studies in Achondroplasia with a site in United States, this one is the 7th largest by planned enrollment of the 20 interventional ones that give a count, is one of 2 that started in 2025, is one of 12 in phase 2, reaches primary completion later than 4 of the 10 other live ones, and was the 27th registered.
47 studies on the registry are indexed under Achondroplasia; 13 are open to participants now.
Browse Achondroplasia studies →8 of the 29 studies in Achondroplasia with a site in United States are open now. Recruiting first, the newest first:
BioMarin Pharmaceutical · Sites in United States, Australia, Canada and 6 more countries
Ages 2–17
QED Therapeutics, a BridgeBio company · Sites in United States, Australia, Canada and 4 more countries
Ages 0 yrs–32 mo
Ascendis Pharma A/S · Sites in United States, Australia, Austria and 12 more countries
Ages 0–2
BioMarin Pharmaceutical · Sites in United States
Ages 0 mo–18 yrs
Johns Hopkins University · Sites in United States
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 9 Achondroplasia studies recruiting now, 2 set no upper age limit and 7 stop at 75 or younger; 9 take children under 18; none take healthy volunteers.
This study: 3 Years to 10 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 15 · Phase 3 6
First in 1996; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 92 is above the median of 74 across 28 interventional studies indexed under Achondroplasia.
Median enrollment 76 across the 20 interventional studies, 271 across the 9 observational. Of the 18 that completed or were terminated, 9 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 29 have an industry lead sponsor. The 9 most frequent:
Tyra Biosciences, Inc is the lead sponsor of 7 studies on the registry; 4 are open to participants now.
Tyra Biosciences, Inc has 1 study filed under Achondroplasia — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 29 studies in Achondroplasia with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety, tolerability, and identify potentially effective dose(s) of TYRA-300 in children with achondroplasia with open growth plates.
This is a Phase 2, multicenter, open-label, dose-escalation study to determine the safety, tolerability, and identify potentially effective dose(s) of TYRA-300, a fibroblast growth factor receptor (FGFR)-3 selective tyrosine kinase inhibitor, in children 3 to 10 years of age with achondroplasia with open growth plates that will examine three cohorts of children: the Sentinel Safety Cohort, Cohort 1, and Cohort 2.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TYRA-300 is provided as sprinkle capsules/mini-tablets. The total dose will be calculated based on the participant's weight. Weight adjustments will be made every 3 months.
Drug: TYRA-300 0.125 mg/kg
TYRA-300 is provided as sprinkle capsules/mini-tablets. The total dose will be calculated based on the participant's weight. Weight adjustments will be made every 3 months.
Drug: TYRA-300 0.25 mg/kg
TYRA-300 is provided as sprinkle capsules/mini-tablets. The total dose will be calculated based on the participant's weight. Weight adjustments will be made every 3 months.
Drug: TYRA-300 0.375 mg/kg
TYRA-300 is provided as sprinkle capsules/mini-tablets. The total dose will be calculated based on the participant's weight. Weight adjustments will be made every 3 months.
Drug: TYRA-300 0.50 mg/kg
TYRA-300 is provided as sprinkle capsules/mini-tablets. The total dose will be calculated based on the participant's weight. Weight adjustments will be made every 3 months.
Drug: TYRA-300 0.625 mg/kg
Drug page: Dabogratinib
Initial dose level of TYRA-300 per protocol, subsequent dose level escalations will occur based on criteria outlined in the protocol.
Drug page: Dabogratinib
Subsequent dose level escalations will occur based on criteria outlined in the protocol.
Drug page: Dabogratinib
Subsequent dose level escalations will occur based on criteria outlined in the protocol.
Drug page: Dabogratinib
Subsequent dose level escalations will occur based on criteria outlined in the protocol.
Drug page: Dabogratinib
Subsequent dose level escalations may occur based on criteria outlined in the protocol.
Incidence of treatment-related adverse events as assessed by CTCAE v5.0
Time frame: Up to 12 months
Change from baseline in annualized growth velocity (Cohort 1)
Time frame: 12 months
Change from baseline in annualized growth velocity (Cohort 1)
Time frame: 6 months
Change from baseline in height z-score (Cohort 1)
Time frame: 6 and 12 months
Pharmacokinetics: maximum plasma concentration (Cmax)
Time frame: 15 days
Pharmacokinetics: time to reach maximum plasma concentration (Tmax)
Time frame: 15 days
Pharmacokinetics: area under the plasma concentration-time curve (AUC)
Time frame: 15 days
Pharmacokinetics: half-life of TYRA-300 (t1/2)
Time frame: 15 days
Pharmacokinetics: apparent total clearance (CL/F)
Time frame: 15 days
Pharmacokinetics: apparent volume of distribution (Vd/F)
Time frame: 15 days
Change from baseline in annualized growth velocity (Cohort 2)
Time frame: 6 and 12 months
Change from baseline in height z-score (Cohort 2)
Time frame: 6 and 12 months
Change from baseline in standing height (cm)
Time frame: 6 and 12 months
Change from baseline in sitting height (cm)
Time frame: 6 and 12 months
Change from baseline in upper and lower arm length (cm)
Time frame: 6 and 12 months
Change from baseline in tibial length (cm)
Time frame: 6 and 12 months
Change from baseline in femur length (cm)
Time frame: 6 and 12 months
Change from baseline in arm span proportionality (arm span/height ratio)
Time frame: 6 and 12 months
Change from baseline in upper segment/lower segment ratio
Time frame: 6 and 12 months
Change from baseline in elbow extension
Time frame: 6 and 12 months
Started Mar 2025 (actual). Primary completion is estimated for Jan 2030, 58 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dabogratinib
Tyra Biosciences, Inc